Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02671435 · ClinicalTrials.gov registry record · Phase 1

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by MedImmune.

Active
Registry status
Phase 1
Development phase
383
Enrollment target
20
Study locations

NCT02671435 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 383 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (95% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02671435, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by MedImmune.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
383 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Bevacizumab
  • DRUG Cetuximab
  • DRUG Durvalumab
  • DRUG Monalizumab
  • DRUG mFOLFOX6

Study Locations (20)

California

  • Research Site - Duarte
  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - Sacramento
  • Research Site - Santa Monica

New York

  • Research Site - New Hyde Park
  • Research Site - New York
  • Research Site - The Bronx

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Scottsdale

Colorado

  • Research Site - Aurora

Florida

  • Research Site - Tampa

Illinois

  • Research Site - Chicago

Maryland

  • Research Site - Baltimore

Trial Details

FieldValue
Enrollment Target 383 participants
Start Date 2016-02-22
Est. Completion 2025-09-01
Phase Phase 1

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02671435

The ClinicalTrials.gov registry entry for NCT02671435 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (95% higher). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT02671435 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Alabama.

Frequently Asked Questions

What is clinical trial NCT02671435 about?

NCT02671435 is a clinical study titled "A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors". This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants ...

What is the current status of trial NCT02671435?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 383 participants. The study started on 2016-02-22. Estimated completion is 2025-09-01.

What conditions does trial NCT02671435 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT02671435?

The interventions under investigation include: Bevacizumab (DRUG), Cetuximab (DRUG), Durvalumab (DRUG), Monalizumab (DRUG), mFOLFOX6 (DRUG).

Who is sponsoring clinical trial NCT02671435?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02671435 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.